Fluticasone furoate/vilanterol
 | |
| Combination of | |
|---|---|
| Fluticasone furoate | Corticosteroid |
| Vilanterol | Ultra-long-acting β2 agonist |
| Clinical data | |
| Trade names | Breo Ellipta, Relvar Ellipta |
| AHFS/Drugs.com | entry |
| Pregnancy category |
|
| Routes of administration | Inhalation (DPI) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| ATC code | R03AK10 (WHO) |
Fluticasone furoate/vilanterol (trade names Breo Ellipta and Relvar Ellipta) is a combination drug for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It contains fluticasone furoate, an inhaled corticosteroid, and vilanterol, an ultra-long-acting β2 agonist (ultra-LABA).
In 2013, the drug was approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema,[1] and the European Medicines Agency approved it as a second-line therapy for the treatment of COPD and asthma.[2]
There are; however, concerns that LABAs such as vilanterol increase the risk of deaths due to asthma.[1]
References
- 1 2 "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. 10 May 2013.
- ↑ "Summary of opinion: Relvar Ellipta" (PDF). European Medicines Agency. 19 September 2013.
External links
- Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) Official Site
- Breo Ellipta (fluticasone furoate and vilanterol) Inhalation Powder, for Oral Inhalation. U.S. Full Prescribing Information
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 09, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.